Helena Anglada-Martínez

Learn More
WHAT IS KNOWN AND OBJECTIVE It is now estimated that about 5% of cetuximab-treated patients and about 3% of panitumumab-treated patients will develop grade 3-4 hypomagnesemia. The aim of this study(More)
OBJECTIVES Mobile phones have been rapidly adopted by the general population and are now a promising technology with considerable potential in health care. However, refusal rates of 24%-75% have been(More)
AIMS Adherence to medication is a major problem that affects 50-60% of chronically ill patients. As mobile phone use spreads rapidly, a new model of remote health delivery via mobile phone – mHealth(More)
  • 1